Abstracts tagged "ACPA"

Abstract Number: 11 • 2018 ACR/ARHP Annual Meeting
PAD4-Independent Interaction of ACPA with Nuclear Antigens in Apoptotic Cells and Neutrophil Extracellular Traps (NETs) Defines a Subset of Autoantibodies
Gustaf Wigerblad¹, Katy A. Lloyd¹, Peter Sahlström², Karine Chemin², Johanna Steen², Philip J. Titcombe^2,3, Diana Zhou², Ragnhild Stålesen¹, Bianka Marklein⁴, Elena Ossipova², Johan Rönnelid⁵, Luca Piccoli⁶, Antonio Lanzavecchia⁶, Daniel L. Mueller³, Karl Skriner⁴, Lars Klareskog², Fredrik Wermeling¹, Vivianne Malmström² and Caroline Grönwall⁷, ¹Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ³The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Dept. of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁶Università della Svizzera italiana, Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁷Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) associated anti-citrullinated protein autoantibodies (ACPA) bind a wide range of citrullinated proteins with high cross-reactivity. Recent findings suggest that certain, but…
Abstract Number: 1481 • 2018 ACR/ARHP Annual Meeting
Are ACPA Associated with More Bone Loss over Time in Patients with RA?
Emma de Moel¹, Josephine Amkreutz¹, Lotte Heimans², Cornelia F. Allaart³, Tom W.J. Huizinga⁴ and Diane van der Woude⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Internal Medicine, Leiden University Medical Center, Leiden, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are one of the most important serological markers for rheumatoid arthritis (RA) and have been suggested to play a pathophysiologic…
Abstract Number: 14 • 2018 ACR/ARHP Annual Meeting
Individual RA-Derived Monoclonal Anti-Citrullinated Protein Autoantibodies (ACPA) Have Extensive Citrulline Multi-Reactivity Demonstrated By a Large-Scale Protein Array Platform
Peter Sahlström¹, Johanna Steen¹, Madeleine Jenning², Philip J. Titcombe^1,3, Ute Nonhoff^4,5, Ragnhild Stålesen⁶, Bianka Marklein², Daniel L. Mueller³, Zoltan Konthur⁴, Karin Lundberg⁷, Anca I. Catrina⁶, Lars Klareskog¹, Vivianne Malmström¹, Karl Skriner² and Caroline Grönwall⁸, ¹Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Dept. of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ⁴Engine GmbH, Hennigsdorf, Germany, ⁵Max Planck Institute of Colloids and Interfaces, Potsdam, Germany, ⁶Rheumatology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁸Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The presence of serum IgG anti-citrullinated protein autoantibodies (ACPA) in rheumatoid arthritis (RA), is associated with more aggressive disease progression. Although ACPA have been…
Abstract Number: 1487 • 2018 ACR/ARHP Annual Meeting
Correlation between Cytokine Levels and Power-Doppler Ultrasound Activity Is BMI Dependent, and Different in ACPA Positive and ACPA Negative RA with Wrist Arthritis
Ottar Gadeholt¹, Erin Arnold², Corinne Gorman³, Tobias Mueller⁴ and William Arnold², ¹Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ²Orthopedics and Rheumatology of the North Shore, Skokie, IL, ³Orthopaedics & Rheumatology of the North Shore, Skokie, IL, ⁴Department of Bioinformatics, University of Wuerzburg, Wuerzburg, Germany
Background/Purpose: Multiple cytokines are assumed to be involved in RA pathogenesis. It has been hypothesized that ACPA-negative RA with wrist affection constitutes a separate entity.…
Abstract Number: 22 • 2018 ACR/ARHP Annual Meeting
Monoclonal Anti-Citrullinated Protein Antibodies Generated from RA-Derived B Cells Recognize Amino Acid Motifs Rather Than Specific Proteins
Johanna Steen¹, Philip J. Titcombe², Bjorn Forsström³, Caroline Grönwall⁴, Anca I. Catrina⁵, Daniel Lightwood⁶, Peter Nilsson⁷, Lars Klareskog¹ and Vivianne Malmström¹, ¹Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden, ²The Center for Immunology, Dept. of Medicine, University of Minnesota Medical School, Minneapolis, MN, ³SciLifeLab, Royal Technology Highschool,, Stockholm, Sweden, ⁴Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ⁵Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁶Antibody-discovery, UCB-Celltech, Slough, United Kingdom, ⁷Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH - Royal Institute of Technology, Stockholm, Sweden, Stockholm, Sweden
Background/Purpose: Rheumatoid arthritis (RA) associated anti-citrullinated protein autoantibodies (ACPA) develop before RA diagnosis, at which point a wide range of citrullinated proteins have been shown…
Abstract Number: 1504 • 2018 ACR/ARHP Annual Meeting
Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Alistair Reid^1,2,3, Michael D Wiese⁴, Robert Metcalf⁵, Mihir D Wechalekar^6,7, Anita Lee^8,9, Catherine Hill^2,10,11, Cindy Hall⁸, Leah McWilliams⁵, Les Cleland⁸ and Susanna Proudman¹², ¹Rheumatology, Royal Adelaide Hospital, NORTH ADELAIDE, Australia, ²Medicine, The University of Adelaide, Adelaide, Australia, ³Medicine, University of Wollongong, Wollongong, Australia, ⁴School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia, ⁵Rheumatology Unit, Royal Adelaide Hospital, South Australia, Adelaide, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia, ⁷Rheumatology, Flinders University, Adelaide, Australia, ⁸Rheumatology, Royal Adelaide Hospital, Adelaide, Australia, ⁹Rheumatology, University of Adelaide, Adelaide, Australia, ¹⁰The Queen Elizabeth Hospital, Adelaide, Australia, ¹¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ¹²Royal Adelaide Hospital, Rheumatology Unit and University of Adelaide, Discipline of Medicine, Adelaide, Australia
Background/Purpose: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define “seropositive” rheumatoid arthritis (RA). Both predict disease course, development of extra-articular features and treatment outcomes.…
Abstract Number: 1356 • 2017 ACR/ARHP Annual Meeting
Is ACPA-Positive RA Still a More Severe Disease Than ACPA-Negative RA? a Longitudinal Cohort Study in RA-Patients Treated from 2000 Onwards
Aleid C. Boer¹, Annelies Boonen² and Annette H.M. van der Helm-van Mil³, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+, Maastricht, The Netherlands, Maastricht, Netherlands, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated-protein antibodies (ACPA)-positive rheumatoid arthritis (RA) is considered as more severe than ACPA-negative RA, because of its association with joint destruction. Clinically relevant joint…
Abstract Number: 65 • 2017 ACR/ARHP Annual Meeting
RA-Associated Antibodies Targeting Post Translational Modification Have Different Osteoclastogenetic Potential
Akilan Krishnamurthy¹, Johanna Steen², Caroline Grönwall³, Gustaf Wigerblad⁴, Camilla Svensson^5,6, Heidi Wähämaa¹, Vivianne Malmström¹, Bence Rethi¹ and Anca I. Catrina¹, ¹Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, ²Dept. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ³Dep. of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ⁵Dept. of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden, ⁶Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Some but not all antibodies against citrullinated modified proteins (ACPA) promote osteoclastogenesis and bone destruction in vitro and in vivo. We aimed to investigate…
Abstract Number: 1376 • 2017 ACR/ARHP Annual Meeting
Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital
Lieve Van Hoovels¹, Julie Jacobs¹, Bert Vander Cruyssen², Stefanie Van den Bremt¹, Patrick Verschueren³ and Xavier Bossuyt⁴, ¹Laboratory medicine, OLV Hospital, Aalst, Belgium, ²Rheumatology, OLV hospital, Aalst, Belgium, ³Division of Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁴Laboratory medicine, University Hospital Leuven, Leuven, Belgium
Background/Purpose: The clinical diagnosis of rheumatoid arthritis (RA) remains a challenge, making serological markers most interesting. The 2010 ACR/EULAR classification criteria for RA take into…
Abstract Number: 327 • 2017 ACR/ARHP Annual Meeting
Association of Anti-Cyclic Citrullinated Peptide Seropositivity and Lean Mass Index with Low Bone Mineral Density in Patients with Rheumatoid Arthritis
Katherine D. Wysham¹, Dolores M. Shoback², Kashif Jafri¹, Sarah L. Patterson³, Gabriela Schmajuk⁴, John B. Imboden Jr.⁵ and Patricia P. Katz⁵, ¹University of California, San Francisco, San Francisco, CA, ²Medicine, San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA, ³Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ⁵Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Osteoporotic fractures are associated with high morbidity and mortality. Persons with rheumatoid arthritis (RA) have twice the risk of osteoporosis-related fracture than age-matched…
Abstract Number: 1383 • 2017 ACR/ARHP Annual Meeting
IMPACT of Smoking in the Expression of Periodontitis and Anticitrullinated Protein Antibodies in Rheumatoid Arthritis
Jerián González Febles¹, Jorge Luis Garnier Rodríguez², Fernando Sánchez-Alonso³, Sagrario Bustabad⁴, Federico Díaz-González⁵, Mariano Sanz Alonso¹ and Beatriz Rodriguez Lozano⁶, ¹Periodontology, Universidad Complutense de Madrid, Madrid, Spain, ²Odontology, Dental Clinic Garnier, S/C Tenerife, Spain, ³Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁵Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁶Rheumatology, Hospital de Canarias, S/C Tenerife, Spain
Background/Purpose: Environmental, genetic and epigenetic factors can induce citrullination of structural peptides by the enzyme PAD, which induce anti-citrullinated protein antibodies (ACPA) preceding RA. Among…
Abstract Number: 410 • 2017 ACR/ARHP Annual Meeting
Association between Anti-Citrullinated Protein Antibody Status and the Incidence of Erosive Disease in Patients with RA
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA is characterized by the production of autoantibodies including anti-citrullinated protein antibodies (ACPAs).1 ACPAs are considered a prognostic indicator for more severe RA and…
Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting
The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Farideh Alasti², Paul Studenic¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
Abstract Number: 413 • 2017 ACR/ARHP Annual Meeting
Economic Burden Associated with Anti-Cyclic Citrullinated Peptide Antibody Positivity in Patients Newly Diagnosed with RA
J An¹, Z Bider², J Kang¹, E Alemao³, SE Connolly³ and TC Cheetham¹, ¹Western University of Health Sciences, Pomona, CA, ²Southern California Permanente Medical Group, Pasadena, CA, ³Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Anti-cyclic citrullinated peptide (anti-CCP) antibody positivity has been suggested as a strong predictor of joint erosion as well as a potential biomarker for guiding…
Abstract Number: 1454 • 2017 ACR/ARHP Annual Meeting
Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics
Damemarie Paul¹, Laura McDonald², Aarti Rao³, Ruthwik Anupindi⁴ and Keith Knapp^5,6, ¹HEOR, Bristol Myers Squibb, Lawrence Township, NJ, ²CORDS, Bristol Myers Squibb, Uxbridge, United Kingdom, ³Analytics, Mu-Sigma, Bengaluru, India, ⁴Analytics, Mu-Sigma, Lawrence Township, NJ, ⁵Arthritis Northwest PLLC., Spokane, WA, ⁶Discus Analytics LLC., Spokane, WA
Background/Purpose: A fixed treatment paradigm often exists for Rheumatoid Arthritis(RA) patient(pts)1. However, RA is a heterogeneous disease and differences in pts’ serostatus affect disease progression.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].